Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	BMJ Publishing Group 2022

Míreanna comhchosúla

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
de réir: Josef S Smolen, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2018)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2021)

Ixekizumab in the treatment of psoriatic arthritis
de réir: Yu. L. Korsakova, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Methotrexate in psoriasis and psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2020)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2016)

Measuring outcomes in psoriatic arthritis
de réir: Ogdie, A, et al.
Foilsithe / Cruthaithe: (2020)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
de réir: Weinstein, SM, et al.
Foilsithe / Cruthaithe: (2021)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
de réir: Kavanaugh, A, et al.
Foilsithe / Cruthaithe: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
de réir: Miller J, et al.
Foilsithe / Cruthaithe: (2021-12-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
de réir: Bruce W. Kirkham, et al.
Foilsithe / Cruthaithe: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
de réir: P.S. Helliwell
Foilsithe / Cruthaithe: (2011-09-01)

Psoriatic arthritis
de réir: FitzGerald, O, et al.
Foilsithe / Cruthaithe: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
de réir: Ogdie, A, et al.
Foilsithe / Cruthaithe: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2021)

What should be the primary target of "treat to target" in psoriatic arthritis?
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
de réir: Helliwell, PS, et al.
Foilsithe / Cruthaithe: (2022)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2020)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
de réir: Gladman, DD, et al.
Foilsithe / Cruthaithe: (2018)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
de réir: April W. Armstrong, et al.
Foilsithe / Cruthaithe: (2024-05-01)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
de réir: Atul Deodhar, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
de réir: Ye, W, et al.
Foilsithe / Cruthaithe: (2021)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
de réir: Mease, PJ, et al.
Foilsithe / Cruthaithe: (2020)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
de réir: Mease, P, et al.
Foilsithe / Cruthaithe: (2017)

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
de réir: April W. Armstrong, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
de réir: Orbai, A-M, et al.
Foilsithe / Cruthaithe: (2019)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
de réir: A. M. Dadalova, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
de réir: A. Egeberg, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
de réir: Ye, W, et al.
Foilsithe / Cruthaithe: (2021)

Current concepts and unmet needs in psoriatic arthritis
de réir: Mahmood, F, et al.
Foilsithe / Cruthaithe: (2017)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2017)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2024)

Psoriatic arthritis: prospects for the future
de réir: Hackett, S, et al.
Foilsithe / Cruthaithe: (2022)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
de réir: Yazji, SM, et al.
Foilsithe / Cruthaithe: (2025)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
de réir: Leung, Y-Y, et al.
Foilsithe / Cruthaithe: (2023)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
de réir: Helliwell, PS, et al.
Foilsithe / Cruthaithe: (2021)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2016)